Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16119132 | 1.00 | ACE (0.46) | ACEITGB3ITGA2BMAPK1KMT2A | |
| SCHEMBL16119166 | 0.83 | PSMB8 (0.36) | ACECTSSCTSKIDO1CTSL | |
| SCHEMBL14118068 | 0.77 | ACE (0.48) | ACEITGB3ITGA2BMAPK1PPARA | |
| SCHEMBL16119290 | 0.77 | ACE (0.48) | ACEITGB3ITGA2BMAPK1PPARA | |
| SCHEMBL16228847 | 0.77 | ACE (0.48) | ACEITGB3ITGA2BMAPK1PPARA | |
| SCHEMBL19316062 | 0.77 | KLK5 (0.43) | CTSSCTSKCTSLCTSB | |
| SCHEMBL17474140 | 0.75 | ACE (0.46) | ACEITGB3ITGA2BMAPK1KMT2A | |
| SCHEMBL12940447 | 0.73 | ACE (0.47) | ACEITGB3ITGA2BMAPK1KMT2A | |
| SCHEMBL11349136 | 0.73 | ACE (0.47) | ACEITGB3ITGA2BMAPK1PPARA | |
| SCHEMBL26980917 | 0.73 | ACE (0.47) | ACEITGB3ITGA2BMAPK1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | ACE 35/4885ITGB3 4686/4885ITGA2B 4664/4885 |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | ACE 35/4885ITGB3 4686/4885ITGA2B 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.